Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

treatments began 24 hours after exposure to B. anthracis spores. Survival rates at 30 days post- exposure were as follows: 90 percent survival with CIP and 100 percent survival with ORI treatment at doses equal to or greater than 3 mg/kg intraperitoneally (multiple dose) or 50 mg/kg intravenously (single dose).

A follow-up experiment showed that ORI or CIP provided significant survival rates even when the start of treatment was delayed to either 36 or 48 hours post-exposure to spores (i.e., until symptoms had begun to appear). In this experiment, ORI was administered at 10 mg/kg once every 2 days while CIP was administered at 30 mg/kg twice daily. Treatments were provided intraperitoneally for 14 days and survivorship was measured at 30 days.

In addition, a single 50 mg/kg intravenous dose of ORI administered 24 hours prior to anthrax exposure provided a 100 percent survival rate at 30 days.

Researchers at USAMRIID and Targanta concluded that their results provide impetus for investigation of whether ORI could serve as an effective therapy for anthrax exposure, requiring fewer doses compared to CIP, or perhaps even as a potential prophylactic agent.

B. anthracis, a bacterium that forms spores and causes anthrax, has been recognized for more than 60 years as a potential biological warfare agent. Such was the case in 2001, when B. anthracis spores were distributed through the U.S. Postal Service, causing 22 cases of anthrax, including five deaths. If treated promptly B. anthracis usually responds effectively to several antibiotics including penicillin, doxycycline and fluoroquinolones (including ciprofloxacin). Though ciprofloxacin is the current standard of treatment for exposure, anthrax has the possibility of being engineered to be multi-drug resistant, which would complicate treatment. The World Health Organization estimates that 50 kg of B. anthracis spores effectively released in a population of 500,000 people would result in 95,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... 2015 , ... Carey Danis & Lowe comments on a new ... Virginia federal court. The court document outlined the judge’s plan to consolidate 26 vaginal ... Carey Danis & Lowe is a personal injury law firm with headquarters in St. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Texas have launched a ‘responsive design’ website to inform potential sinus surgery patients ... them. , The website includes information about a wide variety of ENT issues ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and ... Summit with the Special Recognition Award for her contribution to the RBMA Coding ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2
... of Pennsylvania School of Medicine have created the first ... a mutation known to produce disease in people, an ... in the October issue of Human Molecular Genetics. ... of vision loss in elderly people, affecting more than ...
... Oct. 9 The following was released,today by the ... MR. TENPAS: Good morning. I am Ronald ... Natural Resources Division here at the,Department of Justice. ... administrator for Enforcement and Compliance Assurance., We ...
... wane over time, study finds , , TUESDAY, Oct. 9 ... who,ve lost weight keep it off, new research suggests. ... of the maintenance programs wears off over time, suggesting ... maintain healthier lifestyles. , "We were excited ...
... a potentially novel way to fight colorectal cancer using ... cancer cells, unlike current treatments that bind to the ... cause unwanted side effects. , In laboratory studies ... system proved able to specifically target colon cancer cells, ...
... NEW YORK, Oct. 9 Highlands Acquisition Corp.,(Amex: HIA.U), ... public offering (the "IPO") of 12,000,000 units. Each unit ... which entitles the holder to,purchase one share of common ... $10.00 per unit, generating gross proceeds of $120,000,000 to ...
... age of 12 currently drink alcohol, according to a ... Services Administration. While the majority of people who drink ... in the expression of violence. , By far the ... violent behavior involves alcohol, says Dr. Jeff Kretschmar, a ...
Cached Medicine News:Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Maintenance Treatment Helps Kids Keep Weight Off 2Health News:Maintenance Treatment Helps Kids Keep Weight Off 3Health News:Maintenance Treatment Helps Kids Keep Weight Off 4Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 3
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: